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Computational T-cell epitope prediction tools have been previously devised to predict potential human 
leukocyte antigen (HLA) binding peptides from protein sequences. These tools are complements of 
Enzyme-linked immunosorbent spot (ELISpot) assays – a very commonly applied immunological 
technique that is used both to identify regions of pathogen genomes that trigger an immune response 
and to characterize the relationships between an individual’s complement of HLA alleles and the degree 
of immunity that they display. If computational tools could accurately predict HLA-peptide binding, 
then these tools might be useable as a cheap and reliable alternative to ELISpot assays.  
A web-based IFN γ ELISpot assay dataset sharing resource, called IMMUNO-SHARE, was developed 
to enable the simple and straightforward storage and dissemination amongst researchers of large 
volumes of IFN γ ELISpot assay data. Such experimental data was next used to make HLA-peptide 
binding predictions with four frequently used T-cell epitope prediction tools – netMHC 3.2, 
IEDB_ANN, IEDB_ARB Matrix and IEDB_SMM. The predictive performances of all four tools 
individually and collectively was statistically assessed using non-parametric Spearman rank-order 
correlation tests. 
It was found that none of the four tested tools yielded binding affinity predictions that were detectably 
correlated with the observed ELISpot data. High false positive rates, where high predicted binding 
affinities between peptides and patient HLAs corresponded in these patients with no appreciable 
immune responses, were apparent for all four of the tested methods. 
The low degree of correlation between ELISpot data and HLA-peptide binding predictions and in 
particular, high false positive rates and relatively low true positive and true negative rates, indicate that 
the four tested tools would require substantial improvement before they could be seen as a viable 
alternative to ELISpot assays. Given that the accuracy of predictions of each of the four methods tested 
is largely dependent on both the quantity and quality of known true binder and true non-binder datasets 
that were used to train the HLA-peptide binding prediction methods implemented by the tools, it is 
plausible that the accuracy of these tools could be increased with larger training datasets. Retraining 
either the current methods or the next generation of prediction tools would therefore be greatly facilitated 
by the availability of large quantities of publically available HLA-peptide binding interaction 
information. It is hoped that IMMUNO-SHARE or some other ELISpot data sharing resource could 
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Abbreviation Definition 
MHC Major Histocompatibility Complex 
HLA Human Leukocyte Antigen 
CTL Cytotoxic T Lymphocytes 
HIV-1 Human Immunodeficiency Virus type 1 
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HCV Hepatitis C virus 
ARV Antiretroviral 
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SMM Stabilized Matrix Method 
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Major Histocompatibility Complex (MHC) molecules are proteins that are expressed on the surface of 
leukocytes (white blood cells). In humans, the MHC encoding genes are located on the short arm of 
chromosome 6 at a location known as the Human Leukocyte Antigen (HLA) region. Molecules within 
this HLA region mediate cytotoxic immune responses [1]. These responses depend on the ability of the 
host’s antigen-specific cells, Cytotoxic T Lymphocytes (CTL) - also called CD8+ T cells - to recognize 
pathogen-derived proteins which are presented to them by HLA molecules (Figure 1.1).  Subsequent 
to their recognizing pathogen-derived proteins, CD8+ T cells attempt to prevent further spread of 
pathogenic microbes within the host by releasing cytotoxic chemicals (called cytokines) which kill 


















Figure 1 .1: Schematic diagram of an infected cell triggering an immune response. (1) The viral peptides infect 
the CD4+ T-cells. (2) The viral peptide is presented by a HLA class I molecule on the surface of the infected cell. 
(3) Recognition of the viral peptide by the CD8+ T-cell is mediated by the T cell receptor (TCR). (4) This 
recognition triggers the CD8+ T-cell to release cytotoxic chemicals (cytokines) which (5) kill the infected cell 
(Figure from [1]). 
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1.1 Pathways that trigger an immune response 
The precise execution of two major pathways - antigen processing and peptide presentation - is required 
to enable CD8+ T-cells to recognize pathogen infected cells (Figure 1.2).  
 
The fundamental purpose of the antigen processing pathway is to generate epitopes – the peptides that 
ultimately trigger an immune response. The generation of epitopes, involves two major steps: 
proteasomal cleavage and peptide transport [2-4]. Within a human immunodeficiency virus type 1 
(HIV-1) infected cell, for example, proteasomal cleavage occurs subsequent to the virus producing its 
own proteins (Gag, Pol, Env, Tat, Vpr, Vif, Rev, Nef, Vpu). These proteins get cleaved into smaller 
fragments (i.e. peptides) by host protein degrading complexes (called proteasomes). This process yields 
subsets of peptides from eight to eleven amino acids in length (also called 8 to 11mers). These peptides 
are then transported from the cytoplasm into the endoplasmic reticulum (ER) by the transporter 
associated with antigen processing (TAP) molecule, leading to peptide presentation: at which point 
binding between the peptides and MHC-I molecules can occur [5]. 
 
The ability of CD8+ T-cells to recognize a specific peptide relies on the affinity with which HLA 
molecules bind the peptide. It has been experimentally demonstrated that in order for a CTL response 




























Figure 1.2: Schematic diagram illustrating the antigen processing and peptide presenting pathways.  Antigen 
processing pathway: (1) Subsequent to a pathogen infection, (2) the host’s proteasome cleaves the pathogen's 
proteins into peptides. (3) These peptides are then transported to the endoplasmic reticulum (ER) by the 
transporter associated with antigen processing (TAP) molecule. (4) Execution of this peptide transport process 
ensures binding between the peptides and the HLA class I molecule. The binding affinity between the peptide 
and HLA class I molecule can either be high (light purple) or low (dark purple).  Peptide presenting pathway: 
the type of binding affinity is important because it affects the ability of the CD8+ T-cells to recognize (5) the 




1.2 Structure of MHC class I molecules 
MHC encoding genes are categorized within one of the three MHC classes: MHC class I, MHC class 
II and MHC class III. The main focus of this study is on MHC class I (MHC-I) molecules, since 
immunity is triggered by these molecules presenting peptides to CTLs. Whereas MHC class II 
molecules present peptides to helper T-cells (a type of leukocyte) which activates B-cells (another type 
of leukocyte) so as to induce antibody secretion, MHC class III molecules regulate inflammation and 
other immune system processes [8].  
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MHC class I molecules are composed of three heavy (α) chain domains (called α1, α2 and α3) and a 
single light chain (called β2-microglobulin) which is encoded on chromosome 15 (Figure 1.3) [1]. The 
top surface between the α1 and α2 domains forms a furrow known as the binding groove. This binding 
groove is the site at which viral proteins bind to the MHC-I molecule to enable viral protein 






Figure 1.3: A diagram indicating the structure of a MHC class I molecule which consists of three heavy (α) 
chain domains (called α1, α2 and α3) and a single light chain (called β2-microglobulin) which is encoded on 
chromosome 15. Between α1 and α2, is the binding groove which enables the pathogen-derived protein to bind 







1.3 Diversity and classification of the MHC class I molecules 
There are three main types of MHC-I molecules, called HLA-A, HLA-B and HLA-C, all of which are 
encoded by different genes.  In addition to these, there are 14 pseudogenes and three genes encoding 
“non-classical” MHC-I molecules, called HLA-E, HLA-F and HLA-G [1].  
 
HLA-A, -B and -C (i.e. the “classical” HLA molecules) are essential in immune responses because 
they present antigenic peptides to CTLs, whereas the role of the non-classical HLA molecules is more 
restricted [9]. Due to the essential role of the classical molecules in immune responses, they have been 
far more extensively studied than the non-classical ones. These studies have revealed a vast degree of 
diversity in the amino acid sequences of the class I α chain such that the genes encoding MHC 
molecules are amongst the most polymorphic regions in the human genome.  
 
According to the HLA nomenclature (http://hla.alleles.org/) there are 10 163 identified classical MHC-
I gene alleles. The most polymorphic of these classical genes, HLA-B, has 4 077 known alleles whereas 
there are 3 285 HLA-A alleles and 2 801 HLA-C alleles [10]. Due to their large numbers, the World 
Health Organization (WHO) Nomenclature Committee for Factors of the HLA System has specifically 
formulated a naming system to differentiate between all of these HLA alleles [11, 12]. To illustrate, an 
HLA-B allele, HLA-B*15:01, is identified by the asterisk (*) and the two sets of unique numbers 
separated by the colon provides detailed information on the HLA allele. In this case, set one indicates 
the allele group, 15, and set two indicates the specific HLA allele, 01.  
 
In addition, HLA alleles are clustered within groups referred to as supertypes.  These supertypes 
indicate the HLA alleles which share specific antigenic binding properties [13]. Such properties depend 
on the physicochemical function of the type of amino acid at particular so-called “anchor residues” 
within an antigenic sequence. Anchor residues are specific amino acid positions (mostly positions two 
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and nine) that firmly secure the antigen within the HLA binding groove and have a disproportionately 
large influence on the ability of an antigen to bind to a specific HLA molecule [14].   
 
There are also various HLA supertypes such as A1, A2, A24, B7, B44 and B58 [15]. For instance, the 
A1-supertype includes several HLA-A alleles (HLA-A*01:01, -A*26:01, -A*29:02 and -A*30:02) 
which bind peptides containing small or aliphatic amino acids in position two and aromatic amino acids 
at the C terminus [16]. The B44-supertype on the other hand consists of a collection of HLA-B alleles 
(HLA-B*1801, -B*40:01, -B*40:02, -B*44:03 and –B*45:01) which recognize peptides that have 
acidic (glutamic and aspartic acid) amino acids in position two and hydrophobic or aromatic amino 
acids at the C terminus [17]. 
 
As a result of the extreme diversity of the classical MHC class I genes, each human carries their own 
rare (and possibly unique) combination of HLA alleles [18]. Although each individual inherits a pair 
of each of the three classical MHC class I genes, the combinations of HLA alleles can vary widely even 
between closely related individuals [1]. 
 
 
1.4 The influence of HLA class I alleles in controlling infectious diseases 
Susceptibility and resistance to numerous infectious diseases such as HIV-1 and hepatitis C virus 
(HCV) have been associated with the polymorphic nature of the HLA complex.  
For example, various studies have indicated that certain HLA alleles are significantly associated with 
either slower or faster HIV-1 disease progression [19-24]. Specifically, whereas HLA-A*24, HLA-
B*8, HLA-B*35, HLA-B*37, HLA-B*53:01, HLA-B*56, HLA-C*04 are associated with more rapid 
disease progression, HLA-A*2, HLA-B*27, HLA-B*51, HLA-B*53, HLA-B*57:01, HLA-B*58:01, 
HLA-C*08 and HLA-C*14 are associated with slower disease progression.  
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Similarly, it has been observed that HLA-A*2301, HLA-B*18 and HLA-C*04 are associated with 
HCV disease progression, whilst resistance to HCV is associated with HLA-A*03, HLA-B*27, HLA-
B*57 and HLA-C*01 [25]. 
 
Ultimately, identifying how a HLA molecule is associated with the progression of an infectious disease 
enables the identification of regions within a pathogen's genome which bind to these HLA molecules. 
For instance, one study identified the epitopes within the HIV-1 subtype B proteome that are 
predominately presented by HLA molecules which are associated with either slower or faster disease 
progression [26]. Whereas HLA molecules associated with slower disease progression bound to Gag-
p24 peptides, those associated with a faster disease progression predominantly bound Nef peptides. 
Furthermore, another study [27] examined the difference in immunological control between (1) slow 
progressors (i.e. HIV-1 infected individuals who manage to control the infection for 10 years or more), 
(2) antiretroviral (ARV) treated progressors and (3) ARV untreated progressors, all of which carried 
the HLA-B*57:01 allele. Each patient’s peripheral blood mononuclear cells (PBMC) were tested for 
the presence of three particular HIV-1 Gag-p24 epitopes which are known to bind to HLA-B*57:01: 
ISPRTLNAW (IW9, Gag147-155), KAFSPEVIPMF (KF11, Gag162-172) and QASQEVKNW (QW9, 
Gag308-316). It was discovered that whereas all these epitopes within the slow progressor group were 
being presented, only the KF11 and IW9 epitopes were being presented within the untreated progressor 
group and only the KF11 epitope was being presented within the treated progressor group.  
 
In conclusion, being able to identify the HLA molecule and epitope combinations which mediate the 
best immune responses against an infectious disease is essential as such knowledge will help inform 





1.5  Computational prediction of HLA class I and epitope interactions  
Computational epitope prediction tools have the potential to complement immunological techniques 
for identifying epitopes such as Enzyme-Linked ImmunoSpot (ELISpot) [29] and Enzyme-linked 
immunosorbent assay (ELISA) [30]. These laboratory techniques are primarily designed to monitor 
immune responses and identify both regions of pathogen genomes that trigger immune responses, and 
the relationships between HLA alleles and immunity [1]. Since these laboratory techniques are 
expensive and time consuming, accurate computational methods for predicting HLA-epitope 
interactions and binding affinities would be extremely valuable. 
 
Given that data generated from laboratory-based investigations of HLA binding have in the past had a 
major impact on epitope-based vaccine development [31, 32], so too could accurate computational 
tools for predicting HLA-epitope interactions. Ideally, faster and cheaper identification of CTL epitopes 
that are suitable for inclusion within vaccines will have a positive effect on the rate at which effective 
individualised vaccines could be designed and manufactured. 
 
To fill this need, a range of epitope prediction tools have been developed. With the aid of these tools, 
identifying T-cell epitopes has become more efficient by minimizing the numbers of in vitro tests that 
need to be carried to identify peptides that are likely to bind to specific HLA alleles [1]. It is important 
to note, however, that although there is widespread acceptance of the value of computational epitope 
predictions, in the absence of solid experimentation, such predictions must always remain hypothetical. 
It is because of this that the utility of these tools remains restricted to focusing laboratory-based binding 






1.5.1  Basic computational epitope prediction methods 
In the following sections, I will describe the various prediction methods employed by the different 
epitope prediction tools. There are two main categories of prediction methods: pattern identifying 
methods and 3D structure oriented methods [33 - 41]. Whereas techniques in the latter category can be 
extremely accurate, they are complex and computationally expensive and, possibly because of this, no 
widely applicable tools have yet been developed. Most epitope prediction tool development has 
focused on less computationally expensive methods which seek to identify patterns of amino acids 
within epitopes that are indicative of an affinity for particular HLA alleles. There are three basic 
categories of these pattern identifying methods: (1) binding motif-based, (2) quantitative binding 
matrix-based and (3) machine learning-based [1]. 
 
1.5.1.1 Binding motif-based methods 
These methods rely on the accurate identification of anchor residues within peptide sequences. The 
frequency of each amino acid at any given peptide position is represented in the form of a binding 
matrix: an experimentally informed data construct (Figure 1.4) [1]. Each HLA allele has its own 
binding matrix which is used to predict binding between a peptide and that respective allele. When 
predicting binding between a peptide and an allele, binding motifs within the peptide are searched for, 
and the success or failure of detecting the expected amino acids at the expected anchor residue locations 






Figure 1.4: An illustration of the binding matrix-based method. The top figure is the MHC class I binding matrix 
for HLA A*0201. This matrix indicates the frequency of all the amino acids (Y-axis) at a given position in the 
peptide sequence (X-axis). The frequency levels are represented by different colours; an amino acid that is 
frequently found at a given peptide position is represented in magenta, while a less frequent amino acid is 
represented in blue. The bottom figure is a classic ten amino acid peptide sequence, with each amino acid being 




1.5.1.2 Quantitative binding matrix-based methods 
Quantitative binding matrix-based methods are extensions of binding motif-based methods. Rather 
than making binary qualitative predictions as to whether a particular peptide will bind to a given HLA 
allele, these methods attempt to quantify the affinity of such bindings so as to improve the accuracy 
with which epitopes can be predicted [1]. Specifically, these methods calculate a score for each amino 
acid at any given position in the peptide sequence. Each score is then represented in the form of a 





1.5.1.3 Machine learning-based methods 
In supervised machine learning, training a method involves using experimental data (i.e. a training 
dataset) to prepare the method so that it will perform accurately on new data (i.e. test datasets). The 
accuracy with which associations that are detected with training datasets can be generalised to identify 
HLA-epitope interactions in the test datasets is dependent on the training process [1]. 
 
 Artificial Neural Networks (ANNs), Hidden Markov Models (HMMs) and Support Vector Machine 
(SVM) approaches are some the better known machine learning-based methods which have been used 
so as to improve the accuracy of T-cell epitope predictions [43 - 46]. 
 
As these methods owe their success to the use of experimental training data, it is important to consider 
that raw experimental data may present certain complexities, such as data quality and quantity, which 
must be suitably addressed to ensure the success of these methods. Failure to filter out biased data and 
account for data limitations can compromise the utility of these methods. Biased training data can result 
in these methods becoming “over-trained” to the point that they will confidently infer an absence of 
binding between strongly binding HLA-epitope pairs that were not closely related to those in the 
training dataset. Also, the data used in training will always be imperfect such that data errors, or even 
unavoidable statistical noise, will undermine the accuracy of the methods that it is used to train. Finally, 
since training datasets must by necessity be derived directly from experimental data, the biggest 
technical issue with assembling a training dataset is performing enough HLA-peptide binding assays 
to produce sufficiently detailed datasets. Given that the most important limitation on the predictive 
power of these methods is the amount of data that is available to train them, the production of large 
publically available datasets detailing the binding-affinities (or even just the binary binding/non-




1.5.2 Publically available epitope prediction tools 
There are currently more than 25 publically available T-cell epitope prediction tools which employ a 
variety of different epitope prediction methods. Although certain tools employ the same or similar 
methods, they differ with respect to: (1) the number of HLA-alleles for which epitopes can be predicted, 
(2) the lengths of peptides that they are capable of testing, and (3) the numbers of peptide-HLA pairs 
used for training the methods (Table 1.1) [1]. Ideally, a prediction tool should allow testing for a variety 
of HLAs with any peptide sequence that falls within the range of known epitope lengths (between 8 
and 12 amino acids).  
 
With the availability of so many epitope prediction tools, users are challenged with carefully selecting 
the appropriate tool for their research. Consequently, studies which evaluate and compare the predictive 
performances of these tools seek to inform the choices that users must make. For example, one study 
[76] used independent experimentally derived test data to evaluate the accuracy of 30 T-cell epitope 
prediction tools. Among the best performing tools based on receiver operating characteristic (ROC) 
analysis (which measures accuracy based on sensitivity [SE] and specificity [SP] statistics [77, 78]; 
refer to Table 1.2) were the tools, netMHC_ANN and IEDB_ANN, as they had reasonably balanced 
SE and SP scores. In contrast, the tools IEDB_SMM and IEDB_ARB yielded high SE scores but 
frequently identified non-binders as binders (i.e. they had high false positive rates and therefore yielded 
low SP scores).   
 
In another study [79] that used test data sourced from a community binding resource and the literature, 
netMHC 3.0 ANN, IEDB_SMM and IEDB_ARB were amongst the 16 T-cell epitope prediction tools 
evaluated for their ability to discriminate between binders and non-binders of HLA-A*02:01. In this 
analysis, a comparison of the predictive performance – based on SE scores – ranked netMHC_ANN as 
the best tool for identifying actual binders, followed by IEDB_SMM and IEDB_ARB. Furthermore, a 
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comparison of each tool's SP scores ranked netMHC_ANN as the best tool for identifying actual non-
binders, followed again by IEDB_ARB Matrix and IEDB_SMM.  
 
To summarize, due to possible overlaps between the training and testing datasets or potential biases in 
each tool's training dataset, conclusions about the accuracy of the tools that were evaluated in these 
studies remain tentative. It is for this reason, that in my study I will use an alternative ELISpot-based 
approach to evaluate the performance of four of the most frequently used (and freely available) epitope 
























Table 1.1: List of several publically available T-cell epitope prediction tools including the prediction method(s) 
employed; the number of HLA alleles for which epitopes can be predicted and the lengths of peptides that they 
are capable of testing. 
 
* Number of MHC class I data for human species only. 
A-D The four prediction tools being analysed in this study. 
1 NetMHC 3.2A Artificial Neural Networks (ANNs) 78 8-14mer http://www.cbs.dtu.dk/services/NetMHC [45, 47-49]
1. ANNB 47 8-14mer [45]
2. ARBmatrix: Quantitative 
matrixC
56 9,10mer [50]
3. Stabilized Matrix Method 
(SMM)D
48 8-11mer [51]
4. NetHMCpan 71 8-14mer [52, 53]
5. IEDB Recommended: Uses 
the consensus, ANN, SMM, 
NetMHCpan, CombLib methods
71 8-14mer
6. Consensus: Combines: ANN, 
SMM, Comblib_Sidney2008
48 8-14mer
7. Comblib_Sidney2008 12 9mer [55]
8. SMMPMBEC 48 8-11mer [56]













http://www.cbs.dtu.dk/services/NetCTL [45, 60 - 64]
ANN 26
ComPred: QM and ANN 58















10 SYFPEITHI 1.0 Binding Motif-based Matrices 33 8-11mer http://www.syfpeithi.de [70]




12 HLAPred QM 54 10-12mer http://www.imtech.res.in/raghava/hlapred/ [72]
13 TmhcPred QM 39 10-12mer http://www.imtech.res.in/raghava/tmhcpred/ [73]
QM (BIMAS)
Binding Motif-based matrices 
(SYFPEITHI1.0)
15 NetTepi 1.0
An integrated method: combine 3 
prediction methods: 1.pMHC 
binding affinity, 2. pMHC stability, 
3. T cell propensity
13 8-14mer http://www.cbs.dtu.dk/services/NetTepi/ [75]
[74]
9 SVMHC
Support Vector Machine 
(SVMHC)
http://www.sbc.su.se/~pierre/svmhc/ [68 , 69]


















Table 1.2: Statistical descriptions of computational predictions with respect to each experimental dataset (Figure 
from [1]) 
 
 Experimental Dataset 
True Positive List True Negative List 
Computational Predictions 
Positive Predictions TP FP 
Negative Predictions FN TN 
Total  TP + FN FP + TN 
    
ROC analysis 
Sensitivity SE= TP/(TP +FN)  
Specificity  SP = TN/(FP +TN) 




Specifically, this study will explore: (1) the design and development of a web-driven ELISpot data 
sharing resource and (2) the use of ELISpot data to test and evaluate the predictive performance of 
these four tools. The latter involves several consecutive steps: (a) the sourcing of ELISpot data; (b) the 
selection of the four MHC class I CTL epitope prediction tools; (c) the installation of four tools on a 
local network cluster; (d) the evaluation of the predictive performances of the CTL prediction tools 










1.6 Aims and objectives 
The project sets out to (1) design and develop IMMUNO-SHARE, an efficient and easily accessible 
web-based ELISpot data sharing resource and (2) use ELISpot assay data to evaluate the predictive 
performance of four epitope prediction tools 
 
Objectives: 
1. Design and develop IMMUNO-SHARE, a web-based ELISpot data sharing resource. 
Manage the storing and sharing of ELISpot assay data in order to ensure that users are able to 
easily upload, browse and download ELISpot data. 
 
2. Assess the predictive capability of four frequently used epitope prediction tools. 
Use ELISpot assay data to test and evaluate the ability of these tools to accurately identify 
actual binders and non-binders.  
 
My hypothesis is that each tool's quantitative and qualitative predictions will, to a degree that 
is indicative of its accuracy, correlate with the unprocessed spot forming unit (SFU) counts that 












2.1 System design of IMMUNO-SHARE, a web-based ELISpot data sharing resource. 
The design and presentation of IMMUNO-SHARE was developed using a combination of HyperText 
Markup Language 5 (HTML5), Cascading Style Sheets (CSS), JavaScript 1.5 
(https:www.javascript.com), Ajax and JQuery-1.10.1 (https://jquery.com).  
 
Django v1.7, a web framework which is written in python (https://www.djangoproject.com), was used 
to develop IMMUNO-SHARE's system functionality. In addition, the relational database (as illustrated 





Figure 2.1: An Entity Relationship Model illustrating IMMUNO-SHARE's relational database. 
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2.2 Evaluating the predictive performance of epitope prediction tools 
2.2.1 IFN γ ELISpot assay dataset 
Initially, this dataset [80] (obtained from the Los Alamos HIV Immunology database 
(http://www.hiv.lanl.gov/content/immunology/hlatem/study1/index.html)) consisted of 3268 records 
of reactive overlapping long peptides (OLPs) and corresponding patient identification codes. This 
dataset was then filtered to ensure that each HLA-allele record consisted of six valid HLA alleles. As 
a result, 2185 peptide-patient records were used for further analysis. These remaining records were 
then further sorted according to the HLA alleles they contained into FASTA formatted files contained 
OLP sequences with each sequence name field containing an associated peptide ID, patient ID, spot 
forming unit (SFU) value and an automatically calculated SFC value. 
 
Given that the peptides in this dataset were generally 18mers, varying from 15 to 20 amino acids and 
overlapping by 10 amino acids, a customized version of the Sequence Demarcation Tool - Linux 32 
bits (SDT_Linux32; [81]) – as thoroughly explained below in section 2.2.7 - was used to determine 
which of these overlapping peptides contained overlapping regions.  
 
2.2.2 Selecting four frequently used epitope prediction tools 
I selected four frequently used MHC class I epitope prediction tools: netMHC 3.2, IEDB_ANN, 
IEDB_ARB Matrix and IEDB_SMM (as indicated in Table 1.2). My focus here was to evaluate tools 
that were open-source, were among the most sensitive and specific, and could be run in a stand-alone 
mode: a requirement for the comparative tests I wished to perform. All four tools were installed and 
computations were performed using facilities provided by the University of Cape Town's ICTS High 





2.2.2.1 NetMHC 3.2 
This tool accepts input epitope sequences in either FASTA or peptide file formats. The latter file format 
may contain a list of up to 5000 individual peptides, one per line, and all a uniform length (which can 
be between eight to twelve amino acids long). Prediction of CTL epitopes is restricted to those that 
bind 78 common HLA molecules where one or more specific HLA molecules may be selected for 
testing. Binding affinity calculations are based either on weight matrices or ANN prediction values 
(where values are presented in nanomolar units (nM)) [1]. 
 
For ANN predictions, peptides that have associated affinity values less than 50nM are classified as 
strong binders (SBs), whereas peptides with associated affinity values between 50nM and 500nM are 
classified as weak binders (WBs). Accordingly, non-binders/non-epitopes (NBs) would be expected to 
display affinity values greater than 500nM [45]. 
 
2.2.2.2 IEDB_ANN 
The Immune Epitope Database and Analysis Resource (IEDB-AR) hosts a collection of regularly 
updated T-cell epitope prediction tools which are specific for MHC class I binding predictions [54]. In 
addition, IEDB-AR provides access to eight prediction methods (refer to Table 1.2) which have all been 
re-trained on larger datasets, thus increasing their predictive performance. Amongst these methods, 
ANN, Average Relative Binding (ARB) and the Stabilized Matrix Method (SMM) are respectively 
ranked as the top performing methods [1].  
 
I chose to test all three of these methods. The ANN method [45], which is hereafter referred to as 
IEDB_ ANN, accepts input files in FASTA file format, where input sequences may be either a 
continuous sequence or a list of individual nine amino acid long peptides (each on an individual line). 
This tool predicts binding between nonameric peptides and a set of 47 different HLA molecules. 
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Binding affinity calculations of these three methods accessed from IEDB-AR are, as with NetMHC 
3.2, based on IC50 values (nM): IC50 values that are less than 50nM indicate SBs and values between 
50nM and 500nM indicate intermediate binders (IB). Further, WBs have values between 500nM and 
5000nM and NBs values greater than 5000nM [1]. 
 
2.2.2.3 IEDB_ARB Matrix 
The ARB matrix method is similar to the qualitative binding matrices method, where a matrix of 
coefficients is constructed from the frequency of each amino acid at any given position in the peptide 
sequence [50].  
 
This method is only accessible through IEDB-AR and it will hereafter be referred to as IEDB_ARB. It 
accepts sequences in FASTA format, which may either contain a continuous sequence or a list of 
individual peptides between eight and eleven amino acids long (each on an individual line and all 
peptides in one file must be the same length). Predictions are based on a binding affinity between 
peptides and a set of 56 different HLA molecules with SBs, IBs, WBs and NBs being classified in the 
same way as IEDB_ANN [1].  
 
2.2.2.4 IEDB_SMM 
SMM is an improvement on the quantitative binding matrices method where weak binding patterns are 
detected and data quality is accounted for [51]. Although this method was initially designed to only 
predict epitopes that bind HLA-A2, an updated version accessible through IEDB-AR can identify 






All the file input requirements for IEDB_SMM are the same as those for IEDB_ARB and 
classifications of SBs, IBs, WBs and NBs are made in the same way as for IEDB_ANN and IEDB_ARB 
[1].  
 
2.2.3 Compiling the testing dataset 
To fairly compare the predictive performance of the four tools, the ten HLA alleles which can be 
analyzed by all the tools were identified – these include A*01:01, A*02:01, A*03:01, A*24:02, 
A*26:01, B*08:01, B*15:01, B*27:05, B*39:01, B*40:01. As a result, the total number of OLPs within 





Table 2.1: List of the ten HLA alleles that are common across the four prediction tools and the total number of 
OLPs within each of the respective HLA allele files 
HLA alleles No. of OLPs HLA alleles No. of OLPs 
A*01:01 295 B*08:01 261 
A*02:01 940 B*15:01 555 
A*03:01 187 B*27:05 64 
A*24:02 311 B*39:01 64 










2.2.4. Evaluating the predictive performance of the tools using the testing dataset 
The performance of the prediction tools was evaluated for eleven common HLA alleles using only the 
corresponding HLA allele FASTA format files. In addition, since most HLA molecules have a strong 
preference for binding nonameric peptides, predictions were made for 9 amino acid long peptides. 
 
Each tool's prediction results were then separated according to the predicted binding type: (i) SB, (ii) 
IB and WB, and (iii) NB. Within each of these three files, the details of the OLP that contained the 
specified nonameric peptide were identified. The records in each of these three files were appended to 
contain the following information: the nonameric peptide, the predicted binding affinity score, the OLP 
sequence and the OLP ID. 
 
2.2.5. Filtering each tool's prediction results 
To begin with, within each of the ten HLA alleles, the nonameric peptide with the strongest binding 
affinity (i.e. lowest binding affinity) for each OLP was identified. For instance, if at least one of the 
OLP's nonameric peptides was predicted as a SB then that nonameric peptide was selected. However, 
if at least one of the OLP's nonameric peptides was predicted as a WB then that nonameric peptide was 
selected. Furthermore, if all the nonameric peptides of an OLP were predicted as a particular type of 
binder, then the nonameric peptide with the lowest binding affinity (i.e. strongest binding affinity) was 
selected. 
 
Thereafter, new datasets were compiled by selecting the nonameric peptide that displayed the strongest 
binding affinity (i.e. lowest binding affinity) across each patient's corresponding HLA alleles. For 
example, an OLP was regarded as a SB if at least one of the identified nonameric peptides was predicted 
as a SB. Similarly, an OLP was regarded as a WB if none of the identified nonanmeric peptides was 
predicted as an SB but at least one of the identified nonameric peptides was predicted as a WB.  
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Moreover, if all the identified nonameric peptides of an OLP were predicted as a particular type of 
binder, then the lowest binding affinity (i.e. strongest binding affinity) was used in order to categorise 
the OLP accordingly. As a result, the records in this new dataset displayed the following information: 
OLP sequence, OLP ID, patient ID, SFU score, automatically calculated SFC score, binding type 
(SB/WB/NB), nonameric peptide and the corresponding predicted binding affinity score (IC50 values 
(nM)). These pared down datasets consisted of a total number of 1774 records for each of the prediction 
tools. Most importantly, they are hereafter referred to as my filtered datasets (provided in Appendix B). 
 
 
2.2.6. Regression analysis of the SFUs and the quantitative predictions of the tools 
Firstly, a Spearman's rank-order correlation test (implemented using R - a free software environment 
for statistical computing and graphing [82]) was used to determine the relative degrees to which SFUs 
could be predicted based on the inferred binding affinity scores yielded by the four epitope prediction 
methods. 
 
Lastly, a Spearman's rank-order correlation test was used to determine the relative degrees to which 
SFUs could be inferred from the strongest predicted binding affinity scores yielded across the four 
epitope prediction methods.  
 
The null hypothesis, H0, for each Spearman rank correlation test is that there is no correlation between 
the ranks of the predicted binding affinity scores and the ranks of the SFU counts, meaning, as the SFU 






2.2.7 Customized computer scripts 
All the computer scripts used in all the analyses conducted are written in python and were run on a 
Linux 32 bit operating system. 
 
SDT_Linux32 [81] was customized to ensure accurate calculation of the sequence similarity scores for 
each peptide sequence pair. This modified version firstly calculates the average score of the amino 
acids present in the respective file where the Block Substitution Matrix 62 (BLOSUM62) score [83] is 
used to calculate each amino acid's substitution score with itself. Thereafter, all the sequences are 
aligned, using Muscle [84] with a gap opening penalty of -10 and a gap extension penalty of zero. 
Lastly, the similarity score for each peptide sequence pair was calculated by using the BLOSUM62 


















3.1 IMMUNO-SHARE, a web-based ELISpot data sharing resource 
Despite the potential utility of ELISpot assay data for increasing the power of computational HLA-
epitope binding predictions, there is at present no publically available ELISpot data repository. I 
therefore developed IMMUNO-SHARE, a web-based resource to enable the sharing of ELISpot data 














3.1.1 System components and features 
My main design consideration during the development of IMMUNO-SHARE was the minimisation of 
demands placed on users. Although it is necessary to create an account in order to upload data to 
IMMUNO-SHARE, users are able to download data without an account. 
 
3.1.1.1  Uploading procedure 
The user-driven addition of data to IMMUNO-SHARE requires two simple steps: (1) the uploading of 
ELISpot data files and (2) the provision of a small amount of additional information to ensure that the 
uploaded files are correctly interpreted. 
 
3.1.1.1.1 File uploads 
For each uploaded ELISpot experiment, IMMUNO-SHARE expects three different files:  
1 A HLA allele, peptide sequence and peptide ID content file. Given that one needs to know the 
HLA combinations of the patient(s) before conducting an ELISpot assay, each patient's six HLA alleles 
must be identified and included in this file. In addition, for each peptide that is used in the ELISpot 
assay, a peptide sequence together with a corresponding peptide identifier must also be included in this 
file. Consequently, IMMUNO-SHARE will determine the validity of this file by searching through the 
file's header (the first line of the file) for the following tags: (a) “HLA” (this tag must be detected six 
times as it will identify the patient's six HLA alleles); (b) “Peptide Sequence”, and (c) “Peptide ID”. 
Moreover, as IMMUNO-SHARE is designed to analyze the uploaded files, records within this file that 
will be selected and used for further analysis should ideally contain the following: (a) six valid HLA 






2 A peptide ID and plate layout file. On account of 96-well plates being the standard format in 
which ELISpot assays are conducted, this file should ideally describe the layout of the peptide(s) within 
the 96-well plate. Firstly, in order to differentiate this file from the uploaded files, IMMUNO-SHARE 
will search for a hashtag (#). The position of this tag is used to indicate that the adjacent columns and 
rows are the numerically labelled column and alphabetically labelled row headers of the 96-well plate.  
Given that there is no standard for the layout of an ELISpot assay, IMMUNO-SHARE seeks to 
understand each user's specific layout by searching for the positive and negative controls using the tags 
“PC” and “NC”, respectively. Most importantly, the order of the peptide(s) must be indicated by the 
peptide identifiers as indicated in file (1). As a result, IMMUNO-SHARE will analyze and validate this 
file by ensuring that the peptide identifiers in this file correspond to those in file 1. In addition, 
IMMUNO-SHARE will exclude empty wells by detecting a dash/hyphen (-) tag. 
 
3  A SFU ELISpot reader data file. ELISpot readers are machines used to read and interpret the 
96-well plates used during ELISpot assays. These computer-based systems scan ELISpot plates and 
count the total number of spots in each well - with each spot referred to as a spot forming unit (SFU).  
IMMUNO-SHARE recognizes this file by detecting the tag “SPOTS NUMBER”. Subsequently, 
IMMUNO-SHARE will detect the numerically labelled column and alphabetically labelled row 
headers of the 96-well plate by searching for a #.  The unprocessed SFU counts from these files will be 
used for further analysis. In order to ensure a general file structure of the three requested files, 
IMMUNO-SHARE accepts excel (.xls) or text (.txt) file formats. Refer to table 3.1 for each file's 









Table 3.1: Upload file specifications: file format restrictions and the required tags in each file 
 
No. File Name File Format Restrictiona Required Tagd 
1 













3 SFU ELISpot Reader Data   
.xls Spots Number 
.txt # 
aThe file format required will be indicated by a file's extension 
b.xls (excel file) 
c.txt (text file)  






3.1.1.1.2    Additional data entry 
In addition to the three expected upload files IMMUNO-SHARE will request that a user add a little 
extra contextual information (Figure 3.2A) so that it can properly interpret the uploaded data. Of 
primary interest here is the total number of cells in each well. A user can also specify at this point, how 
many replicates of each sample were examined.  
 
3.1.1.1.3 Uploading options 
In order to make the upload process as easy as possible, IMMUNO-SHARE provides both drag-and-
drop and browsing-based upload options: 
1. Drag and Drop.  As seen in Figure 3.2.B, this uploading option enables the three requested files 




2. Browse. For this uploading option, two of the requested files (a) HLA alleles, Peptide Sequence 
and Peptide ID Content File, and (b) Peptide ID and Plate Layout File) are selected for upload by 
clicking on the respective browse buttons (as illustrated in Figure 3.3.B). Thereafter, unprocessed SFU 
data can be copied and pasted directly from the ELISpot reader data file into the space provided (as 
indicated in Figure 3.3.C). 
 
Upon successful completion of an upload, the submitted dataset is immediately available for download 








Figure 3.2: These two images show the two sections in the drag and drop uploading option. A. This data entry 
section provides extra information to help IMMUNO-SHARE understand the implementation of the ELISpot 







Figure 3.3: This image shows the three sections when uploading using the browse option. A. This data entry 
section provides extra information to help IMMUNO-SHARE interpret how the ELISpot assay was carried out. 
B. The browse buttons for uploading the two requested files. C. This textbox is reserved for pasting the 




3.1.2  Automatically generated files 
With every successful upload the following two files are generated. 
 
 A master file. First and foremost, as a unique design feature of IMMUNO-SHARE, the requested 
unprocessed SFUs are automatically adjusted to SFCs per million total cells (SFC/106). This calculation 
is based on the number of cells added in a well and the reported unprocessed SFU counts. With regards 
to any replicates, an average of the unprocessed SFUs is firstly calculated and this average SFU count 
is adjusted accordingly. Furthermore, IMMUNO-SHARE automatically compiles the relevant 
information from all three uploaded files into one “master file”. As a result, records within this comma-
separated value (.csv) file include the Patient ID, Peptide Sequence, the six HLA alleles, SFU counts 
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and SFC/106 counts. 
 
 A SFC/106 bar graph. For a graphical display of the adjusted SFU values from the 96-well plate, 
IMMUNO-SHARE automatically plots a bar graph image (in portable network graphics (.png) format) 
using R - a free software environment for statistical computing and graphing [82].  
 
 
3.1.3  Downloading files 
IMMUNO-SHARE users are able to download any of the files within the available datasets. Each 
dataset consists of the following five files: (1) an HLA allele, peptide sequence and peptide ID content 
file; (2) a peptide ID and plate layout file; (3) a SFU ELISpot reader data file; (4) a master file; and (5) 
a SFC/106 bar graph file. 
 
 
 Testing the predictive power of epitope detection tools in the context of ELISpot experiments  
I attempted to test the hypothesis that four commonly used computational epitope identification tools – 
netMHC3.2, IEDB_ANN, IEDB_ARB Matrix and IEDB_SMM – were capable of predicting the outcome 
of ELISpot experiments. If any of these four tools were able to determine the binding affinities of random 
peptides with even a moderate degree of accuracy, my rationale was that they should be able to predict (to 
some detectable degree at least) the outcome of ELISpot experiments. Specifically, I used Spearman's rank-
order correlation tests to determine whether the estimated epitope binding affinities yielded by each of the 
four HLA-epitope binding prediction tools had any power to predict observed SFU counts in ELISpot 






As is indicated in Table 3.3, the null hypothesis that the HLA-epitope binding predictions had no 
power to predict the outcome of ELISpot experiments was only rejected for IEDB_ARB Matrix. 
However, the positive correlation (as indicated by rs = 0.052) is not expected if stronger binding 
affinities (i.e. lower IC50 values) are associated with higher SFU counts.  It is clear therefore that all 
four of these popular HLA-epitope binding prediction tools performed very poorly in this test with 
none of the methods yielding predictions of SFU counts that were better than those that could be 






Table 3.3:  Spearman rank test for a correlation between SFU counts and predicted binding affinity scores 
yielded by the four epitope prediction methods.  
Prediction tools p-value Rho  
netMHC 3.2 0.90 -0.003  
IEDB_ANN 0.13 0.036 
IEDB_ARB Matrix   0.03 0.052 
IEDB_SMM 0.21 -0.030 



































































Figure 3.5: Scatter plots graph of observed SFU counts in ELISpot experiments against the predicted binding 
affinity scores yielded by the four epitope prediction methods, netMHC 3.2, IEDB_ANN, IEDB_ARB Matrix 
and IEDB_SMM. A spearman rank correlation test failed to reveal significantly negative correlations (i.e. 




 Testing the correlation between the SFUs and the strongest predicted binding affinity scores 
across the four prediction methods  
Given that none of the four tested epitope detection methods was on their own capable of predicting observed 
SFU counts for common HLA-alleles in ELISpot experiments, I also attempted to determine whether 
combining the methods would yield an increase in predictive power. This meta-analysis involved testing the 
correlation between the observed SFUs and the strongest binding affinity (i.e. the lowest binding affinity 
score) inferred across all four of the tools so as to determine whether these tools might be effectively 
combined to give more reliable results.  
 
The result of the Spearman's rank-order correlation test carried out on these combined binding affinity 
estimates yielded a rho of 0.0256 (i.e. a regression line with a positive slope rather than the expected negative 
slope) and a p-value of 0.281.  This test therefore also failed to reject the null hypothesis that there was no 
association between the binding affinity scores and SFU counts, indicating that even when the results of all 


















Figure 3.6: Scatter plot of the observed SFU counts in ELISpot experiments against the strongest predicted 














































Strongest Predicted Binding Affinity Across The Four Tools
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4.  DISCUSSION AND CONCLUSION 
This study explored, (1) and development of IMMUNO-SHARE, a web-driven ELISpot data sharing 
resource and (2) the use of ELISpot data to evaluate the predictive performance of four frequently used 
CTL epitope prediction tools (netMHC 3.2, IEDB_ANN, IEDB_ARB Matrix and IEDB_SMM). 
 
Ideally predictors of HLA-epitope binding should be able to accurately infer whether a given peptide 
sequence is likely to bind to a particular HLA molecule so as to induce an immune response in a patient 
that would then be detectable in an ELISpot assay. Put another way, in the ELISpot datasets that were 
analysed here, every overlapping peptide that was associated in these datasets with an immune response 
in a particular patient should ideally have contained at least one nonameric peptide that was identifiable 
as a binder to at least one of that patient’s HLA alleles. Further, it might be expected that as SFU counts 
increase (i.e. immune responses become stronger), so too should the predicted strength of binding (i.e. 
IC50 scores should decrease).  
 
When plotting SFU counts against predicted binding affinity scores, points representing high SFU 
counts and low predicted binding affinity scores (i.e. true positives) will be situated in quadrant four 
of the plot (Figure 4.1). Furthermore, points representing low SFU counts and high binding affinity 
scores (i.e. true negatives) will be situated in quadrant one. Conversely, points in quadrant two will 
represent SFU counts and predicted binding affinity scores that are both high (i.e. these points indicate 
false positives) and points in quadrant three will represent SFU counts and predicted binding affinity 
scores that are both low (i.e. these points indicate false negatives). 
  
Ideally, a good predictor should have a high degree of sensitivity (i.e. yield a high frequency of true 
positives) and specificity (i.e. yield a high frequency of true negatives) (refer to Table 1.2). 
Consequently, in Figure 3.5, it is expected that the methods that best predict binding affinities between 
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particular HLA Alleles and particular peptides should have the highest numbers of plotted points 





Figure 4.1: An illustration of quadrants within the scatter plots graphs of the observed SFU counts in an 
ELISpot experiment against the predicted binding affinity scores yielded by the prediction tools represented 
in Figure 3.5.  Points in Figure 3.5 that fall within quadrant 1 are true negatives (TN) in that they represent 
low SFU counts and low binding affinities (i.e. with high binding affinity scores). Points in Figure 3.5 that 
fall within quadrant 2 are false negatives (FN), in that they represent both high SFU counts and low predicted 
binding affinity (i.e. with high binding affinity scores). Points in figure 3.5 that fall in quadrant 3 are false 
positives (FP) in that they represent both low SFU counts and high predicted binding affinities (i.e. low 
binding affinity scores). Points in figure 3.5 that fall in quadrant 4 represent true positives (TP) in that they 




The predictive performances of all four tools was statistically measured using a non-parametric 
Spearman rank-order correlation test, which indicated that none of the four tested tools yielded binding 
affinity predictions that were detectably associated with observed ELISpot SFU counts (Table 3.3). As 
38 
 
can be seen in quadrant 3 of the scatter plot graphs of predicted binding affinity scores against observed 
SFU counts in Figure 3.5, all of the tools yielded high frequencies of false positive binding predictions 
(i.e. points representing between 0 and 500 SFU counts and below 25 000 predicted binding affinity 
scores).  The low numbers of points in quadrant four of all four scatter plots in Figure 3.5 indicates that 
all four of the tested methods also yielded only low frequencies of true positive binding predictions 
(i.e. points representing between 501 and 1000 SFU counts and below 25 000 predicted binding affinity 
scores). This implies that in order for such tools to have a degree of predictive utility that rivals actual 
ELISpot-based determination of peptide-induced immune responses, substantial advances need to be 
made in the quantitative prediction of peptide-HLA interactions that are likely to induce immune 
responses.  
 
Furthermore, the generally low numbers of true negative binding predictions, represented by low 
frequencies of points within quadrant one of all four scatter plots in Figure 3.5 (i.e. points representing 
between 0 and 500 SFU counts and predicted binding affinity scores above 25 000), suggests that, in 
general, the four tested tools perform very poorly with respect to identifying true negatives – i.e. they 
have low specificity. This problem is particularly apparent with the netMHC 3.2 and IEDB_SMM 
methods.  
 
It should be emphasised that the approach that has been used here to test the four epitope prediction 
tools is especially harsh. The intention of the test that was performed was to determine the divide 
between what is presently possible with respect to epitope prediction, and what is desirable: a 
computational approach that will accurately predict the strength of an immune response that is induced 
by a given peptide within a given individual.  In this regard, the four methods that were tested had a 
significant disadvantage in that peptide binding predictions were made for only a subset of the HLA-
alleles that were present within the tested individuals.  None of the tested methods are capable of 
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making peptide binding predictions for the full spectrum of alleles present within these tested 
individuals. Therefore, the possibility existed that, in many cases, detected SFU counts produced by 
these individuals in response to particular peptides could have been driven by binding of these peptides 
to HLA alleles that remained untested. If the tested epitope prediction tools performed perfectly, 
instances where an untested HLA-allele was responsible for an observed immune response should have 
yielded low binding affinity predictions for the tested HLA alleles and therefore should have been 
identifiable as points within the false negative quadrants (quadrant two) of the scatter plots in Figure 
3.5. The lack of points within quadrant two of these scatter plots (i.e. points representing between 501 
and 1000 SFU counts and above 25 000 predicted binding affinity scores) strongly suggests that the 
main issue with the four tested analysis tools is not false negative prediction. In the context of the 
extreme test that these tools have been subjected to, false negative predictions would have, in fact, been 
a good sign of specificity.   
 
The high false positive rate yielded by the tools analysed in this study – particularly prediction results 
from IEDB_ARB Matrix and IEDB_SMM – corroborates the findings of another study which 
evaluated the accuracy of several T-cell epitope prediction tools [76]. However, the predictive 
performance of all tools in this study - especially the low frequencies of true positive binding 
predictions by netMHC 3.2 – contradicts the observations of other epitope prediction tool evaluation 
studies [76, 79]. Although high sensitivity scores were observed in these other studies, it should be 
pointed out that the tools were tested with datasets containing test peptides that were included within 
the training datasets of the tools: a factor which means that the apparently high degree of selectivity 
reported in these studies could have potentially been attributable to over-training and that the results of 





The highly inaccurate predictions made by the four tested tools indicates that users of these tools should 
not rely on predictions from individual tools. Over the years, users have been advised to combine 
results from multiple prediction tools in order to obtain greater accuracy, as illustrated by Trost et al 
[79]. However, just as was the case when the results of the four tools were analysed separately, when 
the results were combined there was still no detectable association between binding affinity predictions 
and observed ELISpot SFU counts. Given that this meta-analysis approach yielded high frequencies of 
false positive binding predictions (i.e. points representing between 0 and 500 SFU counts and binding 
affinity scores below 25 000) and failed to yield high frequencies of false negative binding predictions 
(i.e. points representing between 501 and 1000 SFU counts and predicted binding affinity scores above 
25 000) - as seen in Figure 3.6, it is apparent that there is no guarantee that combining the results from 
the four analysed tools will substantially increase the reliability of predictions. 
 
As this study indicates, all four of the prediction tools that were analysed would need to improve the 
accuracy with which they can predict HLA-peptide binding in order for their use to be a reliable 
alternative to ELISpot experiments. There are a number of ways in which such improvements could 
be made, including: (1) expanding the repertoire of HLAs that these methods can test (presently only 
the common HLAs can be tested); (2) the development of new methods within these tools to better 
identify non-binders (so as to reduce false positives); (3) the development of new meta-tools where 
multiple different tools are combined to yield higher degrees of specificity and sensitivity than can be 
achieved with any of the tools individually, and (4)  the training of tools using vastly expanded datasets 
of known HLA-binders and non-binders than have currently been used to train the existing tools. In 
regard to this latter option, Lin et al [76] has suggested that the specificity and sensitivity of these tools 
could be significantly improved simply by retraining them using larger training datasets. An important 
potential application of the IMMUNO-SHARE database that has been developed here could be the 
identification of large numbers of additional HLA-peptide binding interactions. These could then be 
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used to vastly increase the pool of known HLA-peptide interactions that are presently used to train the 
binding prediction tools that have been examined here. Besides the quantity of data used to train the 
tools, another very pertinent factor will be the quality of the binding data. If binding predictions can 
indeed be made using large volumes of ELISpot data that are placed in the public domain, it will be 
important to demonstrate that the quality of this data is high enough to enable the accurate definition 
both of true binders and non-binders and of peptides that will induce immune responses and peptides 





















5. FUTURE WORK 
Once sufficient IFN γ ELISpot assay datasets are uploaded to IMMUNO-SHARE, it will be possible 
to directly predict large numbers of peptide-HLA binding pairs that do bind and even larger numbers 
of pairs that do not.  These large datasets of true positive and true negative binders could then be used 
to massively augment the datasets that have been used to train the present generation of epitope 
prediction tools. 
 
Further, IMMUNO-SHARE can be modified to incorporate longitudinal IFN γ ELISpot assay data. 
For instance, IFN γ ELISpot assay datasets containing peptides sampled early in infection and at 
different points in time (i.e. 12 months, 3 years and etc.) can be linked together. This can provide more 
information of novel binders and non-binders and, most importantly, will help identify sets of single 
amino acid substitutions that specifically abolish binding.  Such data is especially useful within the 
context of training and testing datasets for epitope prediction tools since it contains examples of 
peptides with highly similar sequences but which have completely different binding affinities to 
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